EDUCATIONAL NOTICE: Peptidings provides information for educational and research purposes only. The compounds in this research cluster are subjects of ongoing scientific investigation at varying stages of development. None of the information presented here constitutes medical advice or a recommendation for use. Consult a qualified healthcare provider before making any decisions about peptide use.
Research Cluster
Cancer & Oncology Peptides
Anticancer peptides are used in cancer treatment and diagnosis—from established somatostatin analogues that have been standard of care for decades to newer targeted therapies in clinical development.
Three compounds are FDA-approved with extensive real-world use. Three more are in various stages of clinical testing. This is a pharmaceutically mature cluster with active pipeline development.
Cluster at a Glance
|
6 Compounds Covered |
3 Approved Drug |
3 Clinical Trials |
|
Approved Drug FDA-approved or equivalent regulatory approval |
Clinical Trials Human clinical trial data (Phase I+) |
BLUF: Bottom Line Up Front
Three FDA-approved drugs anchor this cluster. Octreotide and Lanreotide are somatostatin analogues used for neuroendocrine tumors and acromegaly—they represent decades of clinical experience. Lutathera (177Lu-DOTATATE) is a peptide receptor radionuclide therapy that delivered a breakthrough in neuroendocrine tumor treatment. The pipeline compounds (Cilengitide, Melflufen, Motixafortide) each target different mechanisms: integrin inhibition, alkylating agent delivery, and CXCR4 antagonism. Melflufen gained accelerated approval for multiple myeloma but was later withdrawn. This cluster shows both the power and the complexity of peptide-based oncology.
In This Article
Compounds in This Cluster
All 6 compounds in the Cancer & Oncology Peptides cluster, organized by mechanism and editorial function. Each grouping reflects how these compounds relate to each other scientifically—not just alphabetically.
Group 1 of 2
The Somatostatin Analogues
Long-established peptide drugs that control tumor growth and hormone secretion through somatostatin receptor activation.
Group 2 of 2
The Clinical Pipeline
Peptide-based oncology candidates at various stages of clinical development with distinct mechanisms of action.
|
|
|
How These Compounds Relate
The oncology cluster divides into two mechanistic families. The somatostatin-based compounds (Octreotide, Lanreotide, Lutathera) all exploit the same biological target—somatostatin receptors overexpressed on neuroendocrine tumor cells. Octreotide and Lanreotide activate these receptors to inhibit hormone secretion and slow tumor proliferation. Lutathera takes this targeting further by using the somatostatin analogue as a delivery vehicle for radioactive lutetium-177, irradiating the tumor from within.
The pipeline compounds each represent a different therapeutic strategy. Cilengitide attempted to starve tumors by blocking integrin-mediated angiogenesis—the biological rationale was sound, but the Phase III trial in glioblastoma was negative. Melflufen used a peptide as a Trojan horse to deliver an alkylating agent specifically to aminopeptidase-rich tumor cells—clever chemistry that initially earned accelerated FDA approval before being withdrawn. Motixafortide blocks the CXCR4 receptor that helps cancer cells hide in the bone marrow microenvironment.
The lesson from this cluster is that peptide-based oncology works best when it exploits a specific receptor that tumors overexpress. The somatostatin analogues succeeded because neuroendocrine tumors have abundant somatostatin receptors. The pipeline failures were more ambitious—targeting mechanisms shared by normal and malignant cells.
| Shared Mechanism | Compounds |
|
Somatostatin Receptor Agonism Activates somatostatin receptors (SSTR2/5) to inhibit hormone secretion and tumor proliferation in neuroendocrine tumors. |
Octreotide, Lanreotide |
|
Peptide Receptor Radionuclide Therapy Uses somatostatin analogue as targeting vector to deliver radioactive payload directly to SSTR-expressing tumor cells. |
Lutathera |
|
Integrin Inhibition Blocks αvβ3/αvβ5 integrins to disrupt tumor angiogenesis and cell adhesion. |
Cilengitide |
|
Peptide-Drug Conjugate Delivery Uses peptide carrier to deliver cytotoxic payload selectively to aminopeptidase-overexpressing tumor cells. |
Melflufen |
|
CXCR4 Antagonism Disrupts tumor-microenvironment interactions by blocking the CXCR4/CXCL12 axis that anchors cancer cells in protective niches. |
Motixafortide |
Plain English
Three drugs here target the same receptor system on neuroendocrine tumors, but with increasing sophistication. Octreotide and Lanreotide slow tumor growth by activating the receptor. Lutathera uses the same receptor as an address label to deliver radiation directly to the tumor—and it worked dramatically in clinical trials. The three pipeline compounds tried different strategies: blocking tumor blood supply (Cilengitide, failed), smuggling a poison into tumor cells via a peptide disguise (Melflufen, approved then withdrawn), and evicting cancer cells from their bone marrow hiding spots (Motixafortide, still in trials). Cancer is hard. Even good ideas often fail in clinical trials.
Stay Current
New research, new articles, no noise
Peptidings publishes long-form peptide research articles grounded in primary literature. Subscribe to get new compound articles, cluster updates, and evidence reviews delivered to your inbox.
Disclaimer: This page is for educational and research purposes only. It does not constitute medical advice, diagnosis, or treatment. The compounds discussed are subjects of ongoing scientific research and have not been evaluated by the FDA for all applications described. Consult a qualified healthcare provider before making any decisions about your health.